Genitourinary Cancers | Specialty

Immunotherapy in Advanced Prostate Cancer, Part II

December 12th 2012

Immunotherapy in Advanced Prostate Cancer, Part I

December 12th 2012

Managing ADT-Associated Skeletal-Related Events

December 12th 2012

Prostate Cancer Management: Introduction and Overview

December 12th 2012

Dr. Mayer on Tivozanib in Kidney and Breast Cancer

November 30th 2012

Erica L. Mayer, MD, MPH, assistant professor of medicine at Harvard Medical School and Dana-Farber Cancer Institute, describes studies involving tivozanib, a potent VEGF receptor tyrosine kinase inhibitor.

Temsirolimus/Bevacizumab Not Superior to Standard Treatment With Interferon/Bevacizumab in mRCC

November 29th 2012

The combination of temsirolimus plus bevacizumab was not superior to interferon plus bevacizumab as first-line therapy for patients with clear cell metastatic renal cell carcinoma.

November 2012: Clinical Trials in Progress for Urologic Cancers

November 14th 2012

Urologists in Cancer Care presents summaries of ongoing research relating to a variety of urologic cancers.

Recently Approved Therapies Bring New Understanding in Management of Prostate Cancer

November 2nd 2012

After many years of treating patients with advanced prostate cancer the same way, a host of new drug approvals has not only changed the way urologists manage prostate cancer but their understanding of the disease as well.

Meeting Addresses Challenges Facing Urology Groups in Cancer Care

November 1st 2012

The 2012 LUGPA Annual Meeting is expected to gather more than 100 urology groups to discuss administrative, technological, regulatory, and medical challenges facing practices.

Targeted Therapies in Advanced Renal Cell Cancer: A Critical Review

October 22nd 2012

In order to help community oncologists optimize patient outcomes, this review summarizes clinical issues associated with specific therapies and the background pivotal data.

Urology Practices Organize to Deliver Comprehensive Cancer Care: An Interview With Daniel R. Saltzstein, MD

October 22nd 2012

Daniel R. Saltzstein, MD, describes steps Urology San Antonio has taken toward creation of a comprehensive urologic care practice, including establishment of a bone health clinic and an advanced prostate cancer clinic.

Axitinib Study Does Not Meet Primary Endpoint as Front-Line Therapy for Renal Cell Carcinoma

October 17th 2012

A phase III study of axitinib as a front-line therapy for metastatic renal cell carcinoma did not meet its primary endpoint of demonstrating a longer median progression-free survival than sorafenib.

Are Physicians Drowning?

October 4th 2012

As with most industries where outcome metrics are crucial for continued success, the government is wanting physicians to deliver care that is outcome- and evidence-based.

Pazopanib Another Front-Line Therapy Option for Metastatic Renal Cell Carcinoma

October 2nd 2012

Pazopanib appears to be another good option for first-line therapy of metastatic renal cell carcinoma along with sunitinib.

Biomarker Predicts Survival Benefit in Advanced Kidney Cancer Treated With TORC1 Inhibitor

September 26th 2012

Pretreatment serum lactate dehydrogenase is a prognostic factor in poor-risk patients with renal cell carcinoma and also a predictive factor for a survival benefit from treatment with temsirolimus.

The Affordable Care Act: An Analysis of Its Impact on Urology Practices

September 20th 2012

For those of us with administrative responsibilities in large urology groups, the dilemma is amplified by the fact that we are affected not only as providers of care but as employers.

Clinical Insights Into Genitourinary Cancer

September 12th 2012

A quick glance at a recent study examining the renal cell carcinoma immunotherapy AGS-003 and the FDA approval of a new noninvasive prostate health index test.

Less Aggressive Surgery Linked to Improved Survival in Older Patients With Kidney Cancer

September 11th 2012

Partial nephrectomy is associated with better overall survival than radical nephrectomy in older patients with early-stage kidney cancer.

Targeted Therapies May Have a Role in Urothelial Cancer

August 28th 2012

Pazopanib has demonstrated activity in a majority of patients with refractory urothelial cancer, providing the first evidence that targeted therapies might have a role in the disease.

Clinical Trials in Progress for Urologic Cancers

August 21st 2012

Summaries of ongoing research underway in bladder, prostate, and renal cancer, intended to stimulate discussion about ongoing clinical trials and to promote collaboration across the urology community.